Development of a Thin Layer Chromatography Method for the Qualitative Detection of Pregabalin in Human Urine
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 16 (2026),
1 January 2026
,
Page 1-5
https://doi.org/10.22037/ijmtfm.v16.52078
Abstract
Background: Pregabalin (PGB) misuse represents a growing public health concern in Algeria, where routine urinary immunoassay screening is limited by elevated cut-off values (≥ 500 µg/L) and cross-reactivity with structurally related compounds, notably gabapentin. This study aimed to develop and validate a simple, low-cost thin-layer chromatography (TLC) method for the qualitative detection of pregabalin in human urine.
Methods: Urine samples were acidified, extracted with ethyl acetate, and spotted onto silica gel plates. Development used a methanol–ammonia mobile phase (98.5:1.5, v/v), and detection was achieved by spraying with ninhydrin reagent followed by heating at 60°C, yielding a characteristic violet spot at Rf = 0.56.
Results: The method demonstrated excellent selectivity (6/6 blank matrices), full specificity against a panel of 30 drugs and substances of abuse, a limit of detection (LOD) of 100 µg/L, and urine stability at −20°C for seven days. Applied to 87 clinical samples, TLC identified 10 false-negative immunoassay results and resolved 7 gabapentin-related false-positive cases, confirming its diagnostic value in resource-limited toxicology settings.
Conclusion: This validated, chloroform-free TLC method provides a cost-effective, selective, and highly sensitive alternative for urinary pregabalin screening, making it an ideal tool for resource-limited toxicology laboratories.
- Forensic toxicology, Drug abuse, Misuse, Immunoassay, Pregabalin
How to Cite
References
[1] Isoardi KZ, Polkinghorne G, Harris K, Isbister GK. Pregabalin poisoning and rising recreational use: a retrospective observational series. Br J Clin Pharmacol. 2020;86(12):2435–40. [DOI: 10.1111/bcp.14348]
[2] Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers. J Clin Pharmacol. 2010;50(8):941–50. [DOI: 10.1177/0091270009352087]
[3] Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13-8. [DOI: 10.1111/j.0013-9580.2004.455003.x]
[4] Golubev RS, Lyust EN, Malkova TL. The choice of the conditions for the preparation of the pregabalin samples from biological fluids using liquid-liquid and solid-phase extraction techniques. Sud Med Ekspert. 2018;61(3):40-3. [DOI: 10.17116/sudmed2018613-43]
[5] Roche S, Blaise M. Prégabaline et risque d’addiction: une nouvelle demande de soin? L’Encephale. 2020;46(5):372-81. [DOI: 10.1016/j.encep.2020.02.008]
[6] Zergui A, Kerdoun MA, Baamar K, Kouadria H, Mekhloufi S, El-Kheir Adjaine O. Pregabalin misuse and abuse in the region of Ouargla, Algeria. Toxicol Anal Clin. 2024;36(4):361-8. [DOI: 10.1016/j.toxac.2024.03.094]
[7] Bounab M, Kolli I, Benfifi H, Mechalikh RT, Amrani D, Ettaieb Errahmani S, et al. Profil de consommation de la prégabaline chez la population féminine de la région centre de l’Algérie entre le 01 janvier 2021 et le 31 mai 2025. Toxicol Anal Clin. 2025;37(3):113-4. [DOI: 10.1016/j.toxac.2025.09.053]
[8] Reisfield GM, Goldberger BA, Bertholf RL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-52. [DOI: 10.4155/bio.09.81]
[9] Bounab M, Kolli I, Rahmani S, Ettaieb Errahmani S, Kaddour R. In utero exposure to pregabalin: interest of meconium analysis – a case report. Fetal Pediatr Pathol. 2026;45(1):28-37. [DOI: 10.1080/15513815.2025.2610269]
[10] Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol. 2014;38(7):387-96. [DOI: 10.1093/jat/bku075]
[11] Ghanem AA, Abo El-Atta H, Shabka O, Gad El-Hak S. Detection of pregabalin in urine using thin layer chromatography: an Egyptian study. Mansoura J Forensic Med Clin Toxicol. 2015;23(1):67-80. [DOI: 10.21608/mjfmct.2015.47317]
[12] Guillen VM, Irizarry L, Connolly MK. Chloroform toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov 9]. [Link]
[13] Friedman M. Applications of the ninhydrin reaction for analysis of amino acids, peptides, and proteins to agricultural and biomedical sciences. J Agric Food Chem. 2004;52(3):385-406. [DOI: 10.1021/jf030490p]
[14] Gupta C, Puri R, Hussain A, Jain S. Development and validation of ninhydrin-based colorimetric spectrophotometric assay for determination of pregabalin in different dissolution mediums. Eurasian J Anal Chem. 2013. [Link]
[15] Guitton J, Gaulier JM, Citterio-Quentin A, Abé E, Allibé N, Bartoli M, et al. Accréditation du criblage toxicologique: recommandations du groupe SFBC — SFTA. Toxicol Anal Clin. 2019;31(1):12-7. [DOI: 10.1016/j.toxac.2019.01.001]
- Abstract Viewed: 49 times
- PDF Downloaded: 38 times